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Biomedical scientists aim to contribute to further understanding of disease pathogenesis
and to develop new diagnostic and therapeutic tools that relieve disease burden. Yet the
majority of biomedical scientists do not develop their academic career or professional
identity as “translational scientists,” and are not actively involved in the continuum from
scientific concept to development of new strategies that change medical practice.
The collaborative nature of translational medicine and the lengthy process of bringing
innovative findings from bench to bedside conflict with established pathways of building
a career in academia. This collaborative approach also poses a problem for evaluating
individual contributions and progress. The traditional evaluation of scientific success
measured by the impact and number of publications and grants scientists achieve is
inadequate when the product is a team effort that may take decades to complete. Further,
where scientists are trained to be independent thinkers and to establish unique scientific
niches, translational medicine depends on combining individual insights and strengths
for the greater good. Training programs that are specifically geared to prepare scientists
for a career in translational medicine are not widespread. In addition, the legal, regulatory,
scientific and clinical infrastructure and support required for translational research is often
underdeveloped in academic institutions and funding organizations, further discouraging
the development and success of translational scientists in the academic setting. In this
perspective we discuss challenges and potential solutions that could allow for physicians,
physician scientists and basic scientists to develop a professional identity and a fruitful
career in translational medicine.
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BUILDING A BRIGHTER FUTURE FOR
TRANSLATIONAL MEDICINE
Biological and medical research has greatly excelled during the
last 50 years with huge advances in understanding disease
pathogenesis. Despite these advances, a large “translational
gap” exists in linking promising scientific discoveries to
therapeutic interventions that improve the outcome of disease
(1, 2). The United States National Institute of Health’s National
Center for Advancing Translational Sciences (NCATS) defined
translational science as “the process of turning observations
in the laboratory, clinic, and community into interventions
that improve the health of individuals and populations—
from diagnostics and therapeutics to medical procedures and
behavioral interventions.” The possibilities for translational
scientists, whether they are physician scientists or basic scientists,
to bring observations from the laboratory to the patient and
vice versa has never been greater. Yet, important barriers exist,
that prevent the participation of biomedical scientists in the
field of translational medicine (Table 1). While physicians have
been traditionally considered as the most likely candidates to
drive the translational scientific field from the bench to bedside
because of their direct interactions with patients, the number
of physicians engaged in research has steadily decreased by
almost 50% between 1985 and 2012 (3). Their participation
has been inhibited by a variety of previously identified factors
including - but not limited to - a lengthy training pathway,
difficulties establishing a career in science alongside practicing
medicine, and accumulation of extensive debt during training
(4, 5). In turn, basic scientists face their own specific obstacles
when pursuing a career in translational science, such as having
limited access to patients and clinical data, and poor alignment
of the academic career and promotion track with the timeline of
translational research. In addition, there are common challenges
faced by both physicians and basic scientists due to the unique
position of translational science bridging academic and clinical
environments. The field of translational science meets a great
need to better connect science and medicine. However, the
unique requirements that come with interdisciplinary and long-
term research projects are vastly different from the traditional
way by which we currently approach biomedical research. In
this perspective we discuss challenges and potential solutions
that could allow for physicians, physician scientists, and basic
scientists to develop a professional identity and a fruitful career
in translational medicine. We hope that this perspective will
increase awareness of existing limitations in biomedical sciences
and spark discussion about the significant shifts needed to move
biomedical sciences toward a future in which new knowledge is
optimally translated into improved medical care.
TRAINING TRANSLATIONAL SCIENTISTS
SHOULD BE INTERDISCIPLINARY AND
COLLABORATIVE
Clinical practice and research are two separate disciplines,
and training as a scientist alongside obtaining a medical
degree is arduous. Medical training has historically been long
and expensive, and has lengthened over time. In addition,
trends in MD program curricula are shifting toward more
specialization, increased focus on health care systems and
delivery of care, and include less scientific knowledge that
informs pathobiology and treatment of disease. In response to
these forces, the American National Institute of Health (NIH)
created the Medical Scientist Training Program (MSTP) to
train physician scientists (https://www.nigms.nih.gov/training/
instpredoc/Pages/PredocOverview-MSTP.aspx). MSTP trainees
follow an integrated training in biomedical science and clinical
practice, and receive a stipend and tuition allowance that
helps reduce debt accumulation. However, the program is very
competitive and currently supports merely ∼1,000 students.
Programs with similar intent exist in Europe (e.g., AKO
program, Maastricht University, The Netherlands), where a 4-
years master program combines patient-oriented research and
medical practice with the goal of translating the results of
scientific research into the practice of patient care. However,
like the MSTP, this program supports only a limited number
of students.
Basic scientists receive highly specialized training, the nature
of which is strongly influenced by their mentor and a small
committee of professors with a similar research focus (6). As
a result, graduate training is prone to have limited breadth
and scope. Further, trainees are often discouraged to venture
outside the scope of their thesis to explore independent
projects as they are expected to work on a project of their
mentor and to graduate within an acceptable time (Table 1).
In contrast, success as a translational scientist requires training
in collaborative and interdisciplinary environments (3). Not
only is close collaboration within diverse teams of scientists
and clinicians essential, translational medicine also involves
participation from non-scientific stakeholders such as intellectual
property officers, investors, patient advocacy groups, ethicists,
and regulatory bodies. Although the strength of the team
comes from the separate expertise of individuals, a common
understanding of the entire process of translational medicine—
including the diverse background, priorities and language of
team members—is critical for successful teamwork. Diversity
in a team increases creativity and likelihood of genuine
innovation (7). Therefore, training in an interdisciplinary
environment is essential for basic scientists to excel in
translational research.
Considerable investment to develop and improve core
programs supporting research career tracks in translational
medicine has been made in the last two decades, and advanced
degree programs in Translational Research have been established
in many universities. Postdoctoral and pre-doctoral candidates
participating in translational medicine programs are exposed to
courses and research projects focusing on topics such as team
building, translational science, clinical research, epidemiology,
translational therapeutics, entrepreneurial sciences, and
biomedical informatics. Interestingly, despite the fact that a
large number of these academic programs are available to
basic scientists and physicians alike, it seems that physician
scientists are more likely to enroll in translational programs. For
example, the large majority of registered students (∼68%) for
the Master of Science in Translational Research at the University
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TABLE 1 | Summary of major problem encountered by scientist pursuing a career in translational science and proposed solutions.
Problem Proposed solution
The incentive and reward system within academia is poorly
aligned with a career track in translational medicine
Academic institutions need to establish better evaluation processes for retention and promotion of their
translational scientists:
- Usingmetrics that recognize the wide range of potential contributions to translational medicine (clinical or
social impact of the work, the degree of risk and innovation, the success in establishing multidisciplinary
collaborations, reaching of specific milestones along the path of a project that could take long to
complete, the successful launch of a product or clinical trial, and their involvement with and recognition
by patient advocacy groups)
- Clear guidelines on how individual contributions to large multidisciplinary efforts are evaluated and
measured
- Individualized or extended tenure clocks that are more proportional to the potential impact and better
reflect the timelines of the work
The number of clinician scientists is declining due to longer
training, high education costs and challenges combining
clinical service and research
- Integrated training in biomedical science and clinical training, with a stipend and tuition allowance that
helps reduce debt accumulation
- Recognition that clinical care and research enrich each other, and clear expectations about the efforts
made toward each appointment
The highly focused training of basic scientists with limited
interdisciplinary or clinical exposure poorly prepares basic
scientist for the collaborative nature of translational medicine
- Training in an interdisciplinary environment, including exposure to the clinic, will prepare basic scientists
to excel in a collaborative translational research environment
- Actively recruiting and encouragement of participation of basic scientists in existing advanced degree
programs in Translational Research with courses and research projects focusing on team building,
translational science, clinical research, epidemiology, translational therapeutics, entrepreneurial
sciences, or biomedical informatics
The unique requirements of translational medicine, such as
significant longer timelines, much larger number of lab
members that can be funded with an average grant, larger
overhead costs extending beyond the immediate duration
and focus of the project, are not met by the current funding
system
- Adjust time lines of grants, possibly by making funding for the next phase conditional on researching
milestones
- Divide increased costs, for example by requiring matching external funding from the research institution,
an industry partner, or a patient advocacy group
- Encourage young scientists to pursue a career in translational medicine by specifically providing
funding for early-career scientists in their translational grants, and by removing restrictions such as a
“time-since-PhD limit” on all personal fellowships in recognition that research does not always follow
the anticipated timescale
Building an infrastructure to promote education and research
in translational medicine is a resource-intensive enterprise
- Creation of and funding for centralized “hubs” or “cores” that are characterized by shared,
multidisciplinary use of expensive laboratory equipment, data power and complex professional skills
(e.g., genomics, imaging, flow cytometry, animal facilities, data, and biobanking) that are necessary to
support large translational research projects
- Create a collaborative and interdisciplinary environment where basic scientists and physician
scientists, clinical personnel, patients and intellectual property officers interact regularly to support new
thinking and to promote translational research
of Pennsylvania were participants in an MD or an MD/PhD
program, while PhD candidates formed only 7% of the student
pool (As of August 2018, http://www.itmat.upenn.edu/mstr-
alumni.html). Research institutes have an incredible opportunity
to improve their translational medicine programs by actively
recruiting more basic scientists to help create a more diverse
population of researchers needed for a well-rounded translational
medicine program.
CAREER EVALUATION AND
ADVANCEMENT OF TRANSLATIONAL
SCIENTISTS
Practicing physician scientists reported major challenges
that limit the ability to engage in both clinical practice
and research, with difficulty of balancing time between
clinical, research, and teaching responsibilities as leading
obstacle (5). Physician scientists are often affiliated with
multiple clinical and research departments, each having
different objectives and interests. Such shared appointments
can easily lead to under appreciation of the efforts of the
physician scientist when individual departments regard time
spent in the other department as “lost time,” preventing
the physician scientist from making a full contribution to
their mission. Instead, clinical and research contributions
should be evaluated in concert and departments should
value the unique insights and experience a dual appointment
can bring.
Performance and progress of basic scientists is mainly
evaluated by the number of publications and authorship
rankings, and by the amount of funding secured. The current
review system and associated metrics result in pressure
to publish promptly and frequently. These dynamics are
important contributors to the increasingly recognized
problems such as lack of reproducibility, invalidated data,
avoidance of risky or team-oriented projects, and ultimately
research waste (8–12). Furthermore, publication impact is
quantified using parameters such as journal impact factor
or H index, numbers that do not correlate with the quality
or the social impact of the published work (13). Another
limitation of this publication-driven environment is that
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individual contributions are impossible to discern and only
first and last authors are fully recognized—although multiple
journals now require a thorough description of individual
contributions of each author in an attempt to give credit
where due.
A large part of the solution resides in establishing evaluation
and promotion processes that are more consistent with the
goal of translational medicine: to improve human health.
Because the nature of translational medicine is vastly different
from current academic customs, academic leadership will
first have to actively promote and reward a collaborative
and translational scientific culture. Only when the value
of translational science is well-embedded in the culture of
universities, can evaluation criteria be developed that are
better aligned with the requirements of translational science.
Appraisal metrics should no longer rely primarily on number
of publications and grants, but also recognize the wide
range of potential contributions to translational medicine. A
portfolio of “productivity” should be considered where not
just the number of publications is included but also the
potential clinical or social impact of the work, the degree of
risk and innovation, successfully establishing multidisciplinary
collaborations, reaching of predefined milestones within a
continuing project, the launch of a product or clinical trial,
and involvement with and recognition by patient advocacy
groups. Institutions need to create clear guidelines that are
well-disseminated on how individual contributions to large
multidisciplinary efforts are evaluated and measured. These
might include specific metrics for the different domains of
the project: design, execution, and analysis in the basic
science and clinical realm as evaluated by reviewers who
can assess those individual contributions. Such a renewed
evaluation process also requires a different composition of
review committees, including interdisciplinary expertise from
researchers, clinicians, and other healthcare professionals.
Consideration should be given to individualized or extended
tenure clocks that are more proportional to the potential
impact of the research and better reflect the timelines of
the work.
TRANSLATIONAL SCIENCE REQUIRES A
DIFFERENT FUNDING SYSTEM
A challenge faced by all translational scientists is that the
unique requirements of translational medicine are not met
by the current funding system. For example, the timeline of
translational science is significantly longer than the duration of
most funding cycles. In addition, amultidisciplinary translational
team is much larger than the average number of lab members
that can be funded with a grant. Lastly, the overhead costs
in translational science are large and often extend beyond the
immediate duration and focus of the project. An example is
the development and maintenance of a biobank. Collecting
well-preserved patient material over extended periods of time
can be of crucial value to multiple translational research
groups and projects, but in the current funding climate it is
difficult to secure sufficient and long-term funding for such
an endeavor. Research institutions could play a key role by
creating an infrastructure that would allow long-term coverage
of such shared resources, for example by creating a Translational
Science Institute with a leadership that actively pursues funding
for core facilities, e.g., through donors or collaborations
with industry.
Securing independent funding has become more challenging,
particularly for young scientists (14). The hypercompetitive
funding situation has led to an academic environment that
discourages collaboration, sharing of resources and open
science practices, and the risk of pursuing projects that
are either long, novel or difficult (15). The strict criteria
and timescales for eligibility and outputs of early-career
grants further encourage the pursuit of readily publishable
research. In the UK, the Medical Research Council, Cancer
Research UK and the Wellcome Trust have now removed
their time-since-PhD limit on all personal fellowships
in recognition that research does not always follow the
anticipated timescale. Funding agencies could further
encourage young scientists to pursue a career in translational
medicine by specifically providing funding for early-career
scientists within larger translational grants. Most beginning
scientists have not built a large network yet, which makes
it difficult to serve as the principal investigator and form a
translational team needed to secure funding and make large
project succeed.
Translational research is a long-term endeavor with uncertain
outcome, and it is understandable that funding agencies have
reservations committing large sums of money to such risky
projects. A solution could be to make funding conditional.
Continued funding could depend on performance and
intermediate results, such as the milestone-driven disbursement
program of the California’s Stem Cell Agency (https://www.
cirm.ca.gov/researchers/managing-your-grant#payment). For
example, the funding agency could fund the patent and a dose-
response study only if animal toxicity studies proved successful.
Another model of conditional funding is to require the additional
funding from a different source. A funding agency could provide
80% of funding for a project on the condition that the other 20%
is covered by a third party. This would be another example of
how having an overarching Translational Science Institute could
facilitate connections between promising projects and potential
funding opportunities. By dividing costs and incorporating
intermediate milestones, the risks for funding agencies are
kept to a minimum. In addition, translational research, in
and of itself, reduces the risk associated with large, long-
term projects by internal peer review. Because translational
research teams are composed of experts with different
backgrounds and skill sets, they can create innovative ideas while
simultaneously the individual group members serve as peer-
reviewers of their team members and as such many pitfalls will
be obviated.
Many private and public funders are now seeking to promote
collaboration and network building between academia and
industry, incentivizing scientists to “think big” and connect
to experts that can help translate their findings (e.g., funding
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for translational medicine by the NCATS, the Collaborative
science award of the American Heart Association, and the
private-public-consortium subsidy “Health-Holland”). This new
recognition of necessity to actively facilitate translational
research pathways has come about through funders’ deeper
knowledge of their own funding successes and failures, and
pressure to be more transparent and accountable to stakeholders
and beneficiaries. Taken together, funding agencies are in a
position to take the lead to reform the scientific climate
and promote translational research and its benefits to society.
By developing a grant system specifically for translational
research, large funding agencies can promote interdisciplinary
research while accommodating long-term timelines inherent
to translational research. By staying in dialogue with the
scientific community and adjusting funding structure to the
current needs, funding agencies will ultimately see a larger
return for their investments and a greater impact in improving
human health.
TRANSLATIONAL SCIENTISTS REQUIRE A
MULTIDISCIPLINARY INFRASTRUCTURE
TO SUCCEED
Building an infrastructure to promote education and research
in translational medicine is a resource-intensive enterprise.
Data suggest that it can show a return on investment (16–
18), however such an infrastructure requires a substantial and
long-lasting investment of money and time in trainees, mentors
and core research facilities. Development and maintenance of
adequate shared infrastructures is also considered a major goal
for academic centers promoting translational research programs
(19, 20). Centralized “hubs” or “cores” that are characterized by
shared, multidisciplinary use of expensive laboratory equipment,
data power and complex professional skills (e.g., genomics,
imaging, flow cytometry, animal facilities, data, and biobanking)
are a necessity to maintain institutional competitiveness among
universities and research centers around the world. As an
example, a central hub named EATRIS (European Research
Infrastructure Consortium) was created across Europe to create
a proper infrastructure for translational research and it currently
includes over 80 top-tier academic institutes (https://eatris.eu). In
addition, many universities have started to developed their own
infrastructure to support translational research. Examples are
valorization offices—tasked with putting academic knowledge to
practical use, through offering advice on collaboration with third
parties, intellectual property and support for licensing, patenting
and entrepreneurship—and a wide variety of incentives for
researchers to engage in knowledge transfer activities and focused
on the importance of shared biobanking (e.g., BBMRI-ERIC,
http://www.bbmri-eric.eu/) and data sharing (e.g., ELIXIR,
https://www.elixir-europe.org/) (21).
In similar fashion, hospitals and healthcare providers, tempted
by the highly interactive research and clinical care aspects
of translational medicine, have started to bring biomedical
research and healthcare delivery together inside one highly
collaborative space. Case in point, The Shirley Ryan AbilityLab,
a rehabilitation hospital born in 2017 from the ashes of
the Rehabilitation Institute of Chicago (RIC) is an example
where clinical and research laboratories have become the heart
of the institution and are both horizontally and vertically
integrated and connected to patient care. Another example
is the recently opened Princess Maxima Center for Pediatric
Oncology in the Netherlands, where an environment is created
where research scientists and physicians, clinical personnel,
patients and intellectual property officers interact regularly to
support new thinking and to promote translational research.
The hope is that this milieu, where research is brought to
the patient and not the other way around, will lead to
the transformation of care with the intent of leveraging the
convergence of science, engineering and technology to rapidly
advance outcomes.
Financial support for building academic infrastructure and
collaborative programs that support translational medicine is
traditionally provided through competitive funding programs
from public national Agencies. In the US, NIH-sponsored
NCATS’ Clinical Translational Science Awards (CTSA, https://
ncats.nih.gov/ctsa) have provided substantial support for the
development of clinical and translational research enterprises
through the establishment of research hubs that provide core
resources, essential mentoring and training in translational
medicine. Examples of such CTSAs are the Institute for
Translational Medicine (ITM, https://chicagoitm.org/) and
Northwestern University Clinical and Translational Sciences
Institute (NUCATS, https://www.nucats.northwestern.edu/).
During the formative years of the CTSA program, several sites
also forged collaborations by creating regional consortia based
on geographic proximity to enable sharing of local resources
and meetings of trainees, including the Chicago Consortium for
Community Engagement (C3)—a collaboration among Chicago
CTSAs—and the Sharing Partnership for Innovative Research
in Translation (SPIRiT) Consortium, a model for collaboration
across CTSA Sites (22).
THE WAY FORWARD TO TRANSLATIONAL
SCIENCE
In summary, to create the translational science discipline
necessary to rapidly bridge the gap between bench and bedside,
highly trained physician scientists and basic scientists that
focus on patient-oriented research outcomes are equally
needed. To allow talented scientists to develop an identity
and career as a translational scientist the current academic
system needs to be reformed. Advances in training and
recruiting translational scientists in academia will ultimately
depend on the research and funding priorities that are set
at a national level. For both physician and basic scientists,
early exposure to clinically-relevant research and educational
programs in a communal interdisciplinary environment
that stimulates opportunities for clinical and biological
ideas to “cross-pollinate” is absolutely necessary. Having
a supportive and well-organized institutional framework,
including a dedicated graduate or postgraduate program
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for translational medicine with accessible mentors suitably
trained in translational medicine is crucial. Importantly, career
evaluation and promotions, and funding opportunities that are
designed to match the unique and complex infrastructure of
translational science are indispensable for translational scientists
to succeed.
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